Evidence map›Paper›PMID 41930172›Full record

ReviewOncology research2026

BRAF

Daniel Burg, Aryeh Babkoff, Omer Or, Noam Olshinka, Jonathan Abraham Demma, Mohamad Adila, Marc Wygoda, Philip Blumenfeld, Judith Diment, Masha Galiner and 11 more

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Daniel BurgFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Aryeh BabkoffFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Omer OrOrthopedic Department, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Noam OlshinkaOrthopedic Department, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Jonathan Abraham DemmaSurgical Department, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Mohamad AdilaFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Marc WygodaRadiotherapy Institute, Sharett Institute for Oncology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Philip BlumenfeldRadiotherapy Institute, Sharett Institute for Oncology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Judith DimentPathology Department, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Masha GalinerRadiology Department, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Yusef AzraqRadiology Department, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Daniela KatzFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Petachia ReissmanDepartment of Surgery, The Hebrew University School of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
Sadie OstrowickiDepartment of Biology, University of Texas, Austin, TX, USA.
Gabriella SebbagDepartment of Molecular Biology & Biochemistry, Rutgers University, Piscataway, NJ, USA.
Narmine ElkhateebFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Anat Hershko MosheFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Dania JaberFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Adi HollanderFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Limor RubinFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Aviad ZickFaculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: -Synovial sarcoma is a rare soft tissue sarcoma. Treatment of synovial sarcoma includes surgery, radiation, pazopanib, and chemotherapy. Targeted therapies, such as B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors, are emerging as a potential treatment option. We describe the sixth case of a BRAF Case description: -We treated a 22-year-old male with a left groin BRAF Conclusion: -Panel sequencing of synovial sarcoma can identify targetable mutations. Treatment of BRAF

Indexed as

Protein Kinase InhibitorsProto-Oncogene Proteins B-rafSarcoma, SynovialHumansImidazolesMaleMutationOximesPathologic Complete ResponseProto-Oncogene MasPyridonesPyrimidinonesTreatment OutcomeYoung AdultBRAF protein, humandabrafenibImidazolesMAS1 protein, humanOximesProtein Kinase InhibitorsProto-Oncogene MasProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibB-Raf proto-oncogenecase reportmitogen-activated protein kinase kinase inhibitorserine/threonine kinase inhibitorserine/threonine kinaseV600ESynovial sarcoma

Identifiers

PMID41930172
PMCPMC13040339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.